Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Four innovative oncology drugs launched (including sugemalimab, pralsetinib, avapritinib, and ivosidenib), covering nine indications. Multiple late-stage registration/pivotal programs. Several drugs incorporated into national guidelines and reimbursement lists in China. Multiple first-in-class or best-in-class candidates advancing (including antibody-drug conjugates and multispecific antibodies)
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China Stone Pharmaceuticals.